Back to today’s briefing

Story perspectives

Revolutionary Gene Therapy Cuts Hemophilia B Bleeds Dramatically

6/19/2025

50 4

Summary

Story summary

A groundbreaking 13-year study in The New England Journal of Medicine reveals that adeno-associated virus (AAV) gene therapy offers a safe and effective long-term solution for severe hemophilia B. Ten patients experienced a dramatic drop in bleeding episodes—from 14 to just 1.5 per year—without any serious side effects, showcasing the therapy's promise for lasting relief.

1 of 1

Story summary

A groundbreaking 13-year study in The New England Journal of Medicine reveals that adeno-associated virus (AAV) gene therapy offers a safe and effective long-term solution for severe hemophilia B. Ten patients experienced a dramatic drop in bleeding episodes—from 14 to just 1.5 per year—without any serious side effects, showcasing the therapy's promise for lasting relief.